|WNS Group CEO Keshav Murugesh|
GlaxoSmithKline ($GSK) has renewed its contract with business process management company WNS ($WNS). The extension of the relationship means GSK will continue to rely on WNS for research and analytics services until at least December 2020.
Mumbai, India-based WNS began providing offshore business analytics services to GSK in 2005 and within a year had more than 80 full-time equivalents working on the Big Pharma's projects. GSK last extended its contract with WNS in 2013, at which time it signed up to continue outsourcing business data analytic tasks to the Indian company for a publicly undisclosed period of time. Now, WNS has revealed it has secured another extension to the contract, setting the relationship up to continue into its fifteenth year.
The deal is a boost for WNS. "We are extremely proud to renew our agreement with GSK. For more than a decade, WNS has been a trusted partner driving evidence-based decisions through high-end research and analytics services," WNS Group CEO Keshav Murugesh said in a statement.
To support the continuation of the important relationship, WNS has invested in the infrastructure it uses to service GSK. "Under the agreement with GSK, WNS has set up a dedicated state-of-the-art Knowledge Center, driven by a team of over 600 industry experts," Murugesh said.
The deal is further evidence of Big Pharma's ongoing interest in outsourcing IT and data analytic services to India. Over the past two years, Novartis ($NVS) and Takeda have both struck IT services deals in India, signing up to work with HCL Technologies and Wipro ($WIT), respectively.
- read the statement